CDMO and Biopharma Services

The question

Are the life-science tools, CDMO, and CRO names priced for a permanent step-down in biopharma R&D intensity and a structurally lower bioprocess consumable run-rate, or for a cyclical trough exiting destocking at the same time the GLP-1 manufacturing build-out and cell-therapy scale-up pull on the same capacity?

Base rates

The reference class is prior post-destocking recoveries across the picks-and-shovels cohort: the 2013-2015 cycle following the Affordable Care Act reset, the 2017-2019 cycle following the biotech funding trough, and the 2009-2011 cycle following the financial crisis. In each case, bioprocess and analytical instrument organic growth troughed near 0% and recovered to 6-9% within 18 months, service and CRO revenue compounded at 8-12% on a two-year lag behind biotech funding, and the equity basket tracked the 70th percentile of healthcare sub-sectors during the second year of recovery. Gross margins recovered roughly half of the peak-to-trough compression within 24 months as fixed-cost absorption returned.

The trailing-twelve-month data on this book is mixed in a useful way. TMO is up roughly 18%, DHR up 3%, A up 15%, IQV up 16%, MTD up 25%, LH up 17%, and DGX up 15% -- the quality compounders are already working. WAT is roughly flat and ICLR is down 23% and RVTY down 3%, telling us the recovery is uneven and the laggards carry the cyclical payoff. Healthcare at the sector level has trailed SPY materially on a trailing-year basis, and the basket's dispersion -- winners already working, CRO names still compressed -- is exactly the pattern that precedes broad catch-up.

The imputed expectation in current multiples on the CRO sub-book (IQV at ~18x forward, ICLR at ~13x forward) is that clinical trial starts stay at 2024 trough levels indefinitely. Biotech XBI has already moved off its low and NIH funding normalizations are tracking the legislative path.

Why consensus is wrong

The sell-side has modeled biopharma destocking as a secular change in inventory policy rather than a cyclical over-correction. Bioprocess consumables -- single-use bags, chromatography resins, filters, media -- are priced for a new normal of sub-5% growth. The actual data from the back half of 2025 shows the destock is through: orders have re-accelerated into mid-single-digits at DHR's bioprocess segment and high-single-digits at TMO's BioProduction business, and the compare turns materially easier through 2026.

The second miss is the GLP-1 manufacturing pull. Every incremental injectable dose of semaglutide, tirzepatide, or a next-wave oral requires aseptic fill-finish capacity, chromatography resins for peptide purification, and analytical instruments for release testing. The tools vendors sell into that build-out regardless of which molecule wins, and the capacity expansion by LLY and NVO alone is a multi-year order book at TMO, DHR, A, MTD, and WAT.

Third, the CRO sub-book is priced for a trial-start drought that is already reversing. IQV's bookings, ICLR's book-to-bill, and the underlying biotech funding data have all turned. The consensus multiple assumes the turn does not happen for another 18 months; the underlying data is running a year ahead of that expectation.

Position construction

The book has two 20% anchors, an instrument and services sleeve, a reference-lab sleeve, and a small recovery optionality tail.

Diversified tools anchors (~40%). TMO at ~20% is the broadest exposure -- analytical instruments, bioprocess, specialty diagnostics, and pharma services in one franchise, with the highest incremental leverage as destock turns. DHR at 20% is the post-Veralto portfolio focused on bioprocess, diagnostics, and life-science instruments; the Cytiva bioprocess segment is the cleanest single read on destock normalization in the group.

Instruments and analytics (~27.3%). A at ~12.5% is the analytical instruments and cell-analysis franchise already back to positive year-on-year. MTD at ~8.6% is the laboratory balances and process analytics compounder whose trailing-year print is the strongest in the book and whose margin profile is the highest. WAT at ~6.2% is the liquid chromatography and mass spectrometry specialist whose flat trailing-year masks a mix shift toward GLP-1 and bioanalytical applications.

CRO recovery book (~15.3%). IQV at ~10.8% is the largest CRO with the most diversified trial mix; bookings and RFP flow have already turned. ICLR at ~4.5% is the deepest drawdown in the book and the highest-beta position to trial-start recovery.

Reference labs (~14.0%). LH at ~7.4% and DGX at ~6.6% are the clinical diagnostics pair whose volume stability and acquired-hospital-lab tailwind are already reflected in trailing-year performance; they are ballast with modest growth, not the main payoff.

Recovery optionality (~3.4%). RVTY at ~3.4% is the reagents, detection, and diagnostics specialist still working through a post-merger reset -- the position is sized as asymmetric optionality on mid-cycle recovery, not as a core holding.

Asymmetric payoff

If bioprocess orders normalize to mid-single-digit growth, the GLP-1 manufacturing pull compounds through 2027, and CRO bookings continue to improve in line with biotech funding, the weighted book returns roughly 15-22% annualized over three years. If China stimulus to research spend stalls and NIH funding flat-lines, the book returns roughly 3-8%. If the bioprocess cycle inflects harder than expected and cell and gene therapy volumes move to commercial scale earlier than scheduled, the right tail is 25-35% with multiple expansion on TMO, DHR, and the CROs simultaneously.

At 60% base, 20% bear, and 20% bull, expected value is roughly +13 to +18% annualized against an SPY base rate near +8%. The payoff is asymmetric because the quality compounders in the book have already de-risked the trailing-year drawdown while the CRO sub-book and RVTY carry the recovery optionality that has not yet been priced.

Three things that would change our mind

1. Bioprocess organic growth at DHR Cytiva and TMO BioProduction printing below 2% on a full-year basis in 2026, indicating the destock is structural rather than cyclical and the recovery we expect is not coming.
2. IQV and ICLR book-to-bill falling below 1.1x for two consecutive quarters, with management citing cancellations from large-pharma sponsors rather than timing of small-biotech starts.
3. A CMS or commercial-payer decision that materially cuts reimbursement for routine clinical laboratory volumes, breaking the ballast thesis on LH and DGX.

What we're explicitly NOT betting on

We are NOT betting on any single therapeutic modality -- small molecule, antibody, cell and gene, or peptide -- winning share. The entire point of this book is to be long the demand for manufacturing and testing services regardless of which molecule class compounds. We are NOT betting on a specific M&A outcome for any holding. We are NOT betting on biotech XBI reaching a particular level; we are betting only that trial starts recover from the 2024 trough. We are NOT betting on China pharma-services spending reaccelerating at a specific pace. We are NOT betting on cell and gene therapy reaching commercial scale on a fixed timeline. The thesis requires only that destocking is behind us, GLP-1 capacity continues to expand, and the CRO cycle mean-reverts. Each is a weaker claim than picking the winning modality, and the book is sized for it.